Alumis (ALMS) Stock Price, Quote, News & History | Benzinga

Alumis Inc (ALMS) Stock Price, Quote, News & History

ALMSNASDAQ

Trade with Public

Trade with Public

$25.48

0.170.65%

Last update: Aug 17, 3:03 PM

Earnings: Q2 2026 Earnings were released on Thu Aug 13th, after the market close

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$25.05

Close

-

Volume / Avg.

302.23K / 1.30M

Day Range

$24.95 - $25.71

52 Wk Range

3.76 - 31.35

Market Cap

$3.30B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

7.43%

Days to Cover

6.11

Recent Alumis Inc. News

Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates

Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.

Vandana Singh

This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & UNTY with Buy ratings. See other analyst views.

Avi Kapoor

This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.

Avi Kapoor

Why Is Alumis Stock Falling Monday?

ALMS stock drops 11% as investors lock in a 239% yearly gain. Analyze the support levels and technical indicators for Alumis Inc. (NASDAQ).

Vandana Singh

Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at benzinga.com/analyst-stock-ratings

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-351.40M

Investing Cash Flow (TTM)

-97.94M

Financing Cash Flow (TTM)

360.93M

Free Cash Flow (TTM)

-351.80M

Capital Expenditure (TTM)

-401.00K

Net Change in Cash (TTM)

-88.41M

Analyst Trends and Forecast

1

Feb

6

Mar

3

1

May

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.91B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

395.30

PB Ratio (TTM)

7.25

Earnings Yield % (TTM)

-16.23%

Earnings Yield % (FWD)

-11.18%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.49

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$63.71M

Debt to Equity

0.08

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$25.05

Close

-

Volume / Avg.

302.23K / 1.30M

Day Range

$24.95 - $25.71

52 Wk Range

3.76 - 31.35

Market Cap

$3.30B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

7.43%

Days to Cover

6.11

About

Sector

Health Care

Industry

Pharmaceuticals

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central n...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Alumis (ALMS) stock?

A

You can purchase shares of Alumis (NASDAQ:ALMS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Alumis (ALMS) competitors?

A

Other companies in Alumis’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Alumis (ALMS) stock?

A

Alumis has a consensus price target of $36.73.

Q

What is the current price for Alumis (ALMS)?

A

The stock price for Alumis (NASDAQ: ALMS) is $25.475 last updated August 17, 2026 at 3:03 PM EDT.

Q

Does Alumis (ALMS) pay a dividend?

A

There are no upcoming dividends for Alumis.

Q

When is Alumis (NASDAQ:ALMS) reporting earnings?

A

Alumis does not have any upcoming earnings scheduled.

Q

Is Alumis (ALMS) going to split?

A

There is no upcoming split for Alumis.

Q

What sector and industry does Alumis (ALMS) operate in?

A

Alumis is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.